2026-04-29T04:08:29Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/234982024-11-28T23:58:07Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud author Santopolo, Giulia author Clemente, Antonio author Gonzalez-Freire, Marta author Russell, Steven M author Vaquer, Andreu: author Barón, Enrique author Aranda Perez, Maria author Socias Mir, Antonia author del Castillo Blanco, Alberto author Borges Sa, Marcio author de la Rica, Roberto 2024-10-04T13:46:26Z 2024-10-04T13:46:26Z 2022-12-15 Santopolo G, Clemente A, González-Freire M, Russell SM, Vaquer A, Barón E, et al. Plasma-induced nanoparticle aggregation for stratifying COVID-19 patients according to disease severity. Sensors Actuators B Chem. 2022 Dec;373:132638. 0925-4005 http://hdl.handle.net/20.500.13003/18529 https://hdl.handle.net/20.500.12105/23498 36124254 10.1016/j.snb.2022.132638 Sensors and actuators. B, Chemical 2-s2.0-85139003989 876020500004 Stratifying patients according to disease severity has been a major hurdle during the COVID-19 pandemic. This usually requires evaluating the levels of several biomarkers, which may be cumbersome when rapid decisions are required. In this manuscript we show that a single nanoparticle aggregation test can be used to distinguish patients that require intensive care from those that have already been discharged from the intensive care unit (ICU). It consists of diluting a platelet-free plasma sample and then adding gold nanoparticles. The nanoparticles aggregate to a larger extent when the samples are obtained from a patient in the ICU. This changes the color of the colloidal suspension, which can be evaluated by measuring the pixel intensity of a photograph. Although the exact factor or combination of factors behind the different aggregation behavior is unknown, control experiments demonstrate that the presence of proteins in the samples is crucial for the test to work. Principal component analysis demonstrates that the test result is highly correlated to biomarkers of prognosis and inflammation that are commonly used to evaluate the severity of COVID-19 patients. The results shown here pave the way to develop nanoparticle aggregation assays that classify COVID-19 patients according to disease severity, which could be useful to de-escalate care safely and make a better use of hospital resources. eng Plasma-induced nanoparticle aggregation for stratifying COVID-19 patients according to disease severity research article